Show simple item record

dc.contributor.authorBegum, Aisha
dc.contributor.authorMishriky, Raafat
dc.contributor.authorAntoun Reyad, Ayman
dc.date.accessioned2021-01-22T09:44:40Z
dc.date.available2021-01-22T09:44:40Z
dc.date.issued2020-12-28
dc.identifier.citationBegum, A., Mishriky, R. and Reyad, A.A. (2020) Brexpiprazole in the acute management of schizophrenia, International Journal of Current Medical and Pharmaceutical Research, 6(12), pp. 5466-5471.en
dc.identifier.issn2395-6429en
dc.identifier.doi10.24327/23956429.ijcmpr202012942en
dc.identifier.urihttp://hdl.handle.net/2436/623890
dc.description© 2020 The Authors. Published by International Journal of Current Medical and Pharmaceutical Research. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://journalcmpr.com/issues/brexpiprazole-acute-management-schizophreniaen
dc.description.abstractBrexpiprazole is a new atypical antipsychotic used for the management of psychiatric conditions including schizophrenia and is associated with fewer extrapyramidal side effects compared to traditional antipsychotics due to its additional serotonergic effect, which may improve cognitive symptoms associated with social function decline in schizophrenia. We searched for randomized controlled-trials (RCT) to review the efficacy and tolerability of brexpiprazole in acute management of schizophrenia using different resources including PubMed, Google Scholar, ClinicalTrials.gov and Cochrane Central Register of Controlled-Trials. Data were extracted for adverse effects, positive and negative syndrome scale (PANSS), Personal and Social Performance scale (PSP), PANSS Excited Component (PEC) and Response Rate >30%. 5 RCT were identified and showed that brexpiprazole was favorable compared to placebo in improving PANSS with a mean difference (MD) -5.40 [confidence interval (CI) -6.98, -3.82] and PSP 3.2 [CI 2.09, 4.32] (P<0.00001). Improvement in PANSS positive, PANSS negative subscales and response rate were significant (P<0.00001). Brexpiprazole led to reduced treatment discontinuation due to adverse effects (risk ratio (RR) 0.58), however an increased risk of akathisia was observed (RR= 1.31) especially at higher doses but did not reach statistical significance. In summary, brexpiprazole improved significantly the symptoms of schizophrenia and is well-tolerated, while long-term research is still required to establish its role, particularly in patients with co-morbidities. These findings will guide clinical teams in supporting patients suffering from schizophrenia.en
dc.formatapplication/pdfen
dc.language.isoenen
dc.publisherIJCMPRen
dc.relation.urlhttps://journalcmpr.com/issues/brexpiprazole-acute-management-schizophreniaen
dc.subjectantipsychoticsen
dc.subjectpsychiatric disordersen
dc.subjectschizophreniaen
dc.subjectbrexpiprazoleen
dc.titleBrexpiprazole in the acute management of schizophreniaen
dc.typeJournal articleen
dc.identifier.journalInternational Journal of Current Medical and Pharmaceutical Researchen
dc.date.updated2021-01-21T16:46:33Z
dc.date.accepted2020-11-08
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW22012021AARen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/en
rioxxterms.licenseref.startdate2021-01-22en
refterms.dateFCD2021-01-22T09:44:28Z
refterms.versionFCDVoR
refterms.dateFOA2021-01-22T09:44:42Z


Files in this item

Thumbnail
Name:
2426-A-2020.pdf
Size:
844.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/